本帖最后由 老马 于 2012-1-13 21:20 编辑
7 ~& F7 e' o- [ t+ f/ I: a# S5 j, M; }5 T e% O
爱必妥和阿瓦斯丁的比较7 H7 c. ^" R/ M/ e, ^6 T& V% [( Y5 n
6 P. X2 m8 r! dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
D: x H9 U; y+ c! B- x
, ]' j) T/ O- {/ P
+ n- t& U# \+ [$ a) e! z! ]& J
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 e2 h$ t) [: S% q
==================================================
4 J, w+ X) `3 A/ v# [: ^) P7 YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% M3 g$ s( H2 g! u' u5 P6 Q4 L
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
m$ R' c2 o- o8 WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ G2 I. ^; h/ B( d( f
|